HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Armata Pharmaceuticals (AMEX:ARMP) with a $7 price target.

March 22, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Armata Pharmaceuticals maintained at Buy by HC Wainwright & Co. with a $7 price target.
The maintenance of a Buy rating and a $7 price target by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on Armata Pharmaceuticals' stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100